Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 133553
- Registration Number
- NCT04691505
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
- First Posted Date
- 2020-12-29
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Yi Luo
- Target Recruit Count
- 46
- Registration Number
- NCT04688021
- Locations
- 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
MTX and Steroid for aGVHD Treatment
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04677868
- Locations
- 🇨🇳
Peking University Institute of Hematology,Beijing, Beijing, Beijing, China
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionDrug: CisplatinProcedure: Computed TomographyDrug: Doxorubicin HydrochlorideDrug: Gemcitabine HydrochlorideBiological: DurvalumabProcedure: Magnetic Resonance ImagingDrug: MethotrexateBiological: PegfilgrastimProcedure: Therapeutic Conventional SurgeryDrug: Vinblastine Sulfate
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 249
- Registration Number
- NCT04628767
- Locations
- 🇺🇸
Kingman Regional Medical Center, Kingman, Arizona, United States
🇺🇸Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
- Conditions
- Interventions
- Procedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: EchocardiographyDrug: LenalidomideProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingDrug: MethotrexateBiological: NivolumabProcedure: Positron Emission TomographyBiological: RituximabProcedure: Ultrasound Imaging
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT04609046
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34647
- Registration Number
- NCT04571697
- Locations
- 🇺🇸
Janssen R&D, Titusville, New Jersey, United States
Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- xiang yang
- Target Recruit Count
- 228
- Registration Number
- NCT04562558
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionRadiation: 3-Dimensional Conformal Radiation TherapyBiological: BlinatumomabProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CytarabineDrug: DexamethasoneDrug: Calaspargase PegolDrug: Hydrocortisone Sodium SuccinateProcedure: Lumbar PunctureDrug: MethotrexateBiological: NivolumabDrug: MercaptopurineDrug: PegaspargaseDrug: PegcrisantaspaseDrug: Vincristine Sulfate
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 300
- Registration Number
- NCT04546399
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
🇺🇸Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 160
- Registration Number
- NCT04547049
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
🇨🇳The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.